Caboxen is identified as a cabozantinib product available in 20 mg and 80 mg strengths. Cabozantinib is a targeted anticancer medicine classified as a tyrosine kinase inhibitor (TKI).
It works by inhibiting several proteins involved in cancer-cell signaling, tumor growth, and blood-vessel formation. Although this targeted mechanism can provide therapeutic benefits in selected cancers, cabozantinib can also affect normal biological processes and cause serious adverse reactions.
Patients should understand the potential risks before starting treatment and remain under regular medical supervision throughout therapy.
Important: The exact dosage form, manufacturer, and product-specific regulatory status of Caboxen require confirmation. Safety and administration instructions must be checked against the prescribing information for the actual product.
1. Important Safety Warnings
Cabozantinib treatment is associated with several potentially serious complications.
Important warnings include:
- Severe or fatal hemorrhage.
- Gastrointestinal perforation.
- Fistula formation.
- Arterial and venous thromboembolic events.
- Severe hypertension.
- Severe diarrhea.
- Liver toxicity.
- Impaired wound healing.
- Proteinuria.
- Osteonecrosis of the jaw.
- Reversible posterior leukoencephalopathy syndrome.
- Embryo-fetal toxicity.
These complications may require treatment interruption, dose modification, or permanent discontinuation under medical supervision.
2. Risk of Serious Bleeding
Cabozantinib may increase the risk of bleeding, including severe or potentially life-threatening hemorrhage.
Patients should inform their oncologist if they have:
- A history of significant bleeding.
- Gastrointestinal bleeding.
- Blood in the urine.
- Frequent unexplained bruising.
- Recent surgery.
- Bleeding disorders.
- Other conditions that increase bleeding risk.
Warning Signs
Seek immediate medical attention if any of the following occur:
- Vomiting blood.
- Black or tarry stools.
- Significant rectal bleeding.
- Coughing up blood.
- Unusual or uncontrolled bleeding.
- Severe unexplained weakness associated with possible blood loss.
Patients should not ignore unexplained bleeding during treatment.
3. Gastrointestinal Perforation and Fistula
Cabozantinib may cause gastrointestinal perforation or fistula formation.
A gastrointestinal perforation occurs when a hole develops in the wall of the stomach or intestine. A fistula is an abnormal connection between two organs or body structures.
These complications can be serious and may require emergency medical treatment.
Symptoms Requiring Attention
- Severe abdominal pain.
- Persistent abdominal tenderness.
- Fever accompanied by abdominal symptoms.
- Unusual passage of fluid or material between body structures.
- Severe gastrointestinal discomfort.
Patients should seek urgent medical evaluation if these symptoms develop.
4. Blood Clots and Thromboembolic Events
Cabozantinib may increase the risk of arterial and venous thromboembolic events.
Examples include:
- Deep vein thrombosis.
- Pulmonary embolism.
- Heart attack.
- Stroke.
- Other serious blood-vessel complications.
Possible Warning Signs
- Sudden chest pain.
- Difficulty breathing.
- Swelling or pain in one leg.
- Sudden weakness on one side of the body.
- Sudden difficulty speaking.
- Sudden changes in vision.
These symptoms require urgent medical assessment.
5. High Blood Pressure
Hypertension is a recognized adverse reaction associated with cabozantinib.
Blood pressure should be checked before treatment and monitored regularly during therapy.
Patients with existing hypertension should discuss blood pressure control with their healthcare professional before starting treatment.
Symptoms of Severe Hypertension
Some patients may not experience noticeable symptoms. Others may develop:
- Severe headache.
- Dizziness.
- Blurred vision.
- Chest discomfort.
- Shortness of breath.
Severe or uncontrolled hypertension may require medical treatment, cabozantinib dose modification, or temporary treatment interruption.
6. Diarrhea and Dehydration
Diarrhea is a common adverse reaction associated with cabozantinib.
Severe or persistent diarrhea can lead to dehydration and electrolyte disturbances.
Patients should contact their healthcare professional if diarrhea becomes persistent, severe, or difficult to manage.
Symptoms of Dehydration
- Dry mouth.
- Increased thirst.
- Reduced urine output.
- Dizziness.
- Weakness.
- Unusual fatigue.
Do not independently change the cabozantinib dose to manage diarrhea.
7. Hand-Foot Skin Reaction
Cabozantinib may cause palmar-plantar erythrodysesthesia, commonly known as hand-foot skin reaction.
This condition affects the palms of the hands and soles of the feet.
Possible Symptoms
- Redness.
- Swelling.
- Tenderness.
- Burning sensations.
- Pain.
- Blistering.
- Peeling skin.
- Difficulty walking or using the hands.
Patients should report skin changes early because timely medical management may help prevent worsening symptoms.
8. Liver Toxicity
Cabozantinib may cause liver-related abnormalities.
Liver function should be assessed before and during treatment according to the prescribing specialist’s monitoring plan.
Patients should report symptoms such as:
- Yellowing of the skin or eyes.
- Dark urine.
- Persistent nausea.
- Unusual tiredness.
- Pain in the upper-right abdomen.
- Unexplained loss of appetite.
Severe liver abnormalities may require treatment interruption or discontinuation.
When cabozantinib is used with another anticancer medicine, additional monitoring may be necessary.
9. Kidney-Related Problems and Proteinuria
Cabozantinib may cause proteinuria, which means an abnormal amount of protein is present in the urine.
Healthcare professionals may request urine tests during treatment to monitor kidney-related complications.
Patients should report:
- New swelling in the legs or face.
- Changes in urine output.
- Unusual foamy urine.
- Sudden weight gain associated with fluid retention.
Severe proteinuria may require treatment modification.
10. Osteonecrosis of the Jaw
Osteonecrosis of the jaw is a rare but serious condition involving damage to jawbone tissue.
Risk factors may include dental disease, invasive dental procedures, and certain concomitant cancer treatments.
Patients should:
- Inform their oncologist about existing dental problems.
- Maintain appropriate oral hygiene.
- Arrange dental assessment when recommended.
- Discuss planned tooth extractions or invasive dental procedures.
- Report persistent jaw pain, swelling, or exposed bone.
Dental procedures should be coordinated with the treating oncology team.
11. Impaired Wound Healing
Cabozantinib may interfere with the body’s normal wound-healing process.
This is particularly important for patients undergoing surgery or invasive procedures.
Patients should inform their surgeon and oncologist about cabozantinib treatment before any planned procedure.
Treatment may need to be temporarily withheld before surgery and should only be restarted when adequate wound healing has occurred, according to the applicable prescribing information and specialist assessment.
12. Reversible Posterior Leukoencephalopathy Syndrome
Reversible posterior leukoencephalopathy syndrome (RPLS), also called posterior reversible encephalopathy syndrome (PRES), is a rare neurological condition that has been reported with cabozantinib.
Possible symptoms include:
- Severe headache.
- Seizures.
- Confusion.
- Visual disturbances.
- Changes in consciousness.
- Other sudden neurological symptoms.
Urgent medical evaluation is necessary if these symptoms develop.
13. Pregnancy and Fetal Risk
Cabozantinib may cause harm to an unborn baby.
Women who are pregnant or could become pregnant should discuss the potential risks with their healthcare professional before treatment.
Patients should receive appropriate guidance regarding effective contraception during treatment and for the recommended period after the final dose.
If pregnancy occurs during treatment, the prescribing specialist should be contacted immediately.
14. Breastfeeding Precautions
Breastfeeding is not recommended during cabozantinib treatment and for the specified period after the last dose according to the applicable reference prescribing information.
Patients should discuss breastfeeding plans with their healthcare professional before starting treatment.
15. Drug Interaction Precautions
Cabozantinib is metabolized through the CYP3A4 pathway.
Certain medicines may increase or decrease cabozantinib exposure.
CYP3A4 Inhibitors
Strong CYP3A4 inhibitors may increase cabozantinib exposure and potentially increase toxicity.
CYP3A4 Inducers
Strong CYP3A4 inducers may decrease cabozantinib exposure and potentially reduce treatment effectiveness.
Patients should disclose all medicines and supplements they use, including:
- Prescription medicines.
- Nonprescription medicines.
- Antibiotics.
- Antifungal medicines.
- Seizure medicines.
- Herbal products.
- Vitamins and dietary supplements.
A healthcare professional should review potential interactions before any medicine is started or discontinued.
16. Patients Who Need Special Medical Assessment
Cabozantinib may require additional precautions in patients with certain medical conditions.
These include individuals with:
- Uncontrolled hypertension.
- Previous serious bleeding.
- Cardiovascular disease.
- A history of blood clots.
- Liver impairment.
- Kidney impairment.
- Gastrointestinal disorders.
- Recent or planned surgery.
- Dental disease.
- Pregnancy or breastfeeding considerations.
The prescribing oncologist must evaluate individual risks before treatment.
17. Monitoring During Cabozantinib Treatment
Regular monitoring is an essential part of safe cabozantinib treatment.
Depending on the patient’s condition, healthcare professionals may monitor:
| Monitoring area | Purpose |
|---|---|
| Blood pressure | Identify hypertension |
| Liver function | Detect liver abnormalities |
| Kidney function | Assess renal health |
| Urine protein | Detect proteinuria |
| Blood tests | Evaluate relevant laboratory changes |
| Calcium levels | Identify electrolyte abnormalities |
| Thyroid function | Monitor thyroid-related changes |
| Skin condition | Identify hand-foot reactions |
| Gastrointestinal symptoms | Detect diarrhea and complications |
| Dental health | Reduce oral complications |
| General condition | Evaluate treatment tolerance |
The frequency of monitoring should be determined by the treating healthcare professional.
18. When to Seek Emergency Medical Attention
Certain symptoms may indicate serious cabozantinib-related complications.
Seek urgent medical attention
- Vomiting blood or significant bleeding.
- Severe abdominal pain.
- Sudden chest pain.
- Sudden difficulty breathing.
- Sudden weakness or speech difficulties.
- Seizures.
- Severe headache with visual changes or confusion.
- Signs of a serious blood clot.
Do not wait for a routine appointment if these symptoms occur.
19. Frequently Asked Questions About Caboxen Safety
1. Is Caboxen safe for everyone?
No. Cabozantinib is not suitable for everyone. A healthcare professional must evaluate the patient’s diagnosis, medical history, and potential treatment risks.
2. Can Caboxen cause serious bleeding?
Yes. Cabozantinib may cause severe or potentially fatal hemorrhage.
3. Can cabozantinib increase blood pressure?
Yes. Hypertension is a recognized adverse reaction. Blood pressure should be monitored throughout treatment.
4. Can Caboxen cause diarrhea?
Yes. Diarrhea is a common adverse reaction and may become severe.
5. Can cabozantinib affect the liver?
Yes. Liver-related abnormalities may occur, so appropriate laboratory monitoring is important.
6. Does cabozantinib increase the risk of blood clots?
Yes. Both arterial and venous thromboembolic events have been reported.
7. Can Caboxen affect wound healing?
Cabozantinib may impair wound healing. Planned surgery and invasive procedures should be discussed with the treating oncologist.
8. Can cabozantinib be taken during pregnancy?
Cabozantinib may cause fetal harm. Pregnancy-related risks and contraception requirements must be discussed with a healthcare professional.
9. Is breastfeeding allowed during treatment?
Breastfeeding is not recommended during treatment and for the specified period after the final dose under the applicable prescribing information.
10. Why is regular monitoring necessary?
Monitoring helps identify adverse reactions, assess treatment tolerance, and support appropriate treatment decisions.
Important Safety Notice
Cabozantinib can cause serious and potentially life-threatening adverse reactions. Patients should understand the risks, follow their prescribed treatment plan, and attend recommended medical appointments.
The safety information for Caboxen must be confirmed against the official documentation for its exact formulation and product identity.